TrogarzoTM and Zilretta® require authorization for commercial members starting Oct. 1

For dates of service on or after Oct. 1, 2018, Trogarzo and Zilretta will be added to the medical drug prior authorization program for Blue Cross PPO (commercial) and BCN HMOSM (commercial) members.

Trogarzo will also be subject to a site-of-care requirement for BCN HMO (commercial) members only, effective Oct. 1, 2018. The site-of-care program redirects members receiving select drugs in an outpatient hospital setting to a lower-cost, alternate site of care, such as the physician's office or the member's home.

See the table below for a summary of the requirements.

Drug name HCPCS code Prior authorization requirement Site-of-care requirement
Trogarzo (ibalizumab-uiyk) J3590 Blue Cross PPO (commercial) and BCN HMO (commercial) BCN HMO (commercial) only
Zilretta (triamcinolone acetonide extended release) Q9993 Blue Cross PPO (commercial) and BCN HMO (commercial) No


You can refer to the opt-out list to see which groups don't require members to participate in these programs. This applies to Blue Cross PPO (commercial) groups only. To access the list, complete these steps:

  1. Visit
  2. Log in to Provider Secured Services.
  3. Click BCBSM Provider Publications and Resources.
  4. Click Newsletters & Resources.
  5. Click Forms.
  6. Click Physician administered medications.
  7. Click BCBSM Medical Drug Prior Authorization Program list of groups that have opted out.

And remember: approval of an authorization request isn't a guarantee of payment. Health care practitioners need to verify eligibility and benefits for members. Members are responsible for the full cost of medications not covered under their medical benefits.

Additional information on medical benefit drugs is available at, on the Blue Cross Medical Benefit Drugs — Pharmacy page and the BCN Medical Benefit Drugs — Pharmacy page.

Posted: July 2018
Lines of business: Blue Cross Blue Shield of Michigan and Blue Care Network